Cantor Fitzgerald Reiterates “Overweight” Rating for Lucid Diagnostics (NASDAQ:LUCD)

Lucid Diagnostics (NASDAQ:LUCD)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $2.00 price objective on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 58.73% from the stock’s current price.

LUCD has been the topic of a number of other research reports. BTIG Research set a $2.00 price target on Lucid Diagnostics in a report on Tuesday, March 25th. Ascendiant Capital Markets raised their price target on Lucid Diagnostics from $7.00 to $7.50 and gave the stock a “buy” rating in a research note on Monday, April 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a research note on Wednesday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $3.50.

Lucid Diagnostics Trading Up 2.4%

NASDAQ LUCD opened at $1.26 on Thursday. The stock has a market capitalization of $132.78 million, a price-to-earnings ratio of -1.11 and a beta of 1.28. The business’s 50 day moving average is $1.35 and its two-hundred day moving average is $1.13. Lucid Diagnostics has a 12-month low of $0.68 and a 12-month high of $1.80.

Institutional Investors Weigh In On Lucid Diagnostics

Hedge funds have recently modified their holdings of the stock. Berkshire Asset Management LLC PA purchased a new stake in shares of Lucid Diagnostics during the 1st quarter valued at about $30,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Lucid Diagnostics in the 1st quarter valued at approximately $37,000. Cubist Systematic Strategies LLC bought a new stake in shares of Lucid Diagnostics in the 1st quarter valued at approximately $39,000. LPL Financial LLC increased its holdings in shares of Lucid Diagnostics by 29.1% in the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock valued at $44,000 after acquiring an additional 12,035 shares during the last quarter. Finally, Sunbelt Securities Inc. bought a new stake in shares of Lucid Diagnostics in the 4th quarter valued at approximately $67,000. 74.01% of the stock is currently owned by hedge funds and other institutional investors.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.